The 11 references in paper A. PERESYPKINA A., M. POKROVSKII V., V. GUBAREVA O., E. LEVKOVA A., А. ПЕРЕСЫПКИНА А., М. ПОКРОВСКИЙ В., В. ГУБАРЕВА О., Е. ЛЕВКОВА А. (2018) “КОРРЕКЦИЯ ГИПЕРТЕНЗИВНОЙ НЕЙРОРЕТИНОПАТИИ ПРОИЗВОДНЫМ ДИМЕТИЛАМИНОЭТАНОЛА 7-16 В ЭКСПЕРИМЕНТЕ // CORRECTION OF HYPERTENSIVE NEURORETINOPATHY BY DIMETHYLAMINOETHANOL DERIVATIVE 7-16 IN EXPERIMENT” / spz:neicon:ksma:y:2018:i:1:p:103-107

1
Ragulina V.A., Kostina D.A., Dovgan A.P., Burda Y.E., Nadezhdin S.V. Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated pathology. Research result: pharmacology and clinical pharmacology. 2017; 3(1): 114124. DOI: 10.18413/2500-235X-2017-3-1-114-124
(check this in PDF content)
2
Konstantinidis L., Guex-Crosier Y. Hypertension and the eye. Curr Opin Ophthalmol. 2016; 27(6): 514-521. DOI: 10.1097/ ICU.0000000000000307
(check this in PDF content)
3
Wong T.Y., Mitchell P. Hypertensive retinopathy. N Engl J Med. 2004; 351: 2310–2317. DOI: 10.1056/NEJMra032865
(check this in PDF content)
4
Khurana A.R., Khurana B., Chauhan S., et al. Hypertensive retinopathy an overview. Haryana J. Ophthalmol. 2014; 7: 64-66.
(check this in PDF content)
5
Cuspidi C., Macca G., Salerno M., et al. Evaluation of target organ damage in arterial hypertension: which role for qualitative funduscopic examination? Ital Heart J. 2001; 2(9): 702-706.
(check this in PDF content)
6
Cuspidi C., Meani S., Valerio C., et al. Prevalence and correlates of advanced retinopathy in a large selected hypertensive population. The Evaluation of Target Organ Damage in Hypertension (ETODH) study. Blood Press. 2005; 14(1): 25-31. DOI: 10.1080/08037050510008805
(check this in PDF content)
7
Kolman S.A., van Sijl A.M., van der Sluijs F.A., van de Ree M.A. Consideration of hypertensive retinopathy as an important end-organ damage in patients with hypertension. J Hum Hypertens. 2017; 31(2): 121-125. DOI: 10.1038/jhh.2016.49
(check this in PDF content)
8
Shabelnikova A.S. Correction of ischemic damage to the retina on application of pharmacological preconditioning of recombinant erythropoietin. Research result: pharmacology and clinical pharmacology. 2016; 2(2): 67-90. DOI: 10.18413/2313-8971-20162-2-67-90
(check this in PDF content)
9
Peresypkina A.A., Gubareva V.O., Levkova E.A., Shabelnikova A.S. Correction of retinal angiopathy of hypertensive type by minoxidil, sildenafil in experiment. Research result: pharmacology and clinical pharmacology. 2016; 2(4): 34-44. DOI: 10.18413/2500235X-2016-2-4-34-44
(check this in PDF content)
10
Shabelnikova A.S., Lutsenko V.D., Pokrovskii M.V., Peresipkina A.A., Korokin M.V., Gudyrev O.S., Pokrovskaia T.G., Beskhmelnitsyna E.A., Hoshenko Y.A. Protective effects of recombinant erythropoietin in ischemia of the retina: the role of mechanisms of preconditioning. Research Journal of Medical Sciences. 2015; 9(4): 200-203. DOI: 10.3923/rjmsci.2015.200.203
(check this in PDF content)
11
Zahng, L., Gu, Y.-h., An, J., et al. Effects of the duration of dark adaptation on the retinal function of normal SD rats. Chinese journal of optometry ophthalmology and visual science. 2013; 15(6): 323-326. Поступила / Received 27.11.2017
(check this in PDF content)